Nouveau Life Pharmaceuticals (NOUV) Releases Krill Oil to Support Healthy Cholesterol Levels and Reduce Inflammation

FORT LAUDERDALE, Fla., July 31, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (OTC Pink: NOUV), a provider of quality all-natural dietary supplements, announced today the release of the newest product in the Company's New Life Naturals™ product line: For Your Health – Krill Oil™.

The For Your Health – Krill Oil™ supplement boosts good cholesterol[1] and reduces inflammation[2]. Dr. Oz touted Krill Oil's benefits in November of 2011 saying, "studies have found that Krill Oil works as effectively as omega-3s from other sources, yet at a much lower dose. Furthermore, Krill Oil has been found to raise our good HDL cholesterol and lower our triglycerides as well."

For Your Health – Krill Oil™ was developed by Nouveau Life as part of the Company's focus on health concerns for Baby Boomers and aging adults; however, Krill Oil provides a wealth of benefits to all ages. The oil derived from Krill is rich in phospholipids, the building blocks for cell membranes, and Essential Fatty Acids including Omega-3, 6 and 9.  Krill Oil is commonly used for high triglycerides, heart disease, high blood pressure, rheumatoid arthritis, menstrual pain, ADHD, osteoporosis, hardening of the arteries, kidney problems, and high cholesterol.

New Life Naturals: For Your Health – Krill Oil™ is available for purchase at the Nouveau Life online store at www.nlpnaturals.com. The recommended dose is one to three tablets daily. Every bottle contains 60 softgels, each containing 500 mg of Krill Oil. The supplement retails for $19.99.

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993

[1] 2004 Study in the Alternative Medicine Review
[2] 2007 Study in the Journal of the American College of Nutrition

SOURCE Nouveau Life Pharmaceuticals, Inc.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.